Ecdysterone and LGD-4033 Interaction: Avoid | Peptide Database

Join others researching Minoxidil — share findings, ask questions, and learn from real experiences Minoxidil is an FDA-approved vasodilator originally developed in the 1970s as an oral antihypertensive medication. Its hair growth properties were discovered as a side effect, and topical formulations (2% and 5%) were subsequently approved for the treatment of androgenetic alopecia. It remains one of only two FDA-approved treatments for pattern hair loss and is available over the counter in most countries. In recent years, off-label oral minoxidil at low doses (0.625-5mg) has gained significant traction among dermatologists and the biohacker community as a more convenient and potentially more effective alternative to topical application, particularly for individuals who find the topical formulation inconvenient or who experience scalp irritation. Minoxidil is a potassium channel opener that acts on ATP-sensitive potassium channels in vascular smooth muscle cells, causing vasodilation. When applied topically or taken orally, it is converted to its active metabolite minoxidil sulfate by the enzyme sulfotransferase (SULT1A1) in hair follicle outer root sheath cells. The sulfated form opens potassium channels in dermal papilla cells and vascular smooth muscle surrounding hair follicles, increasing local blood flow and nutrient delivery. Beyond vasodilation, minoxidil upregulates vascular endothelial growth factor (VEGF) expression, extends the anagen (growth) phase of the hair cycle, increases follicle size, and stimulates the transition of resting follicles from telogen into anagen. It also has anti-fibrotic properties that may benefit the perifollicular environment. Notably, minoxidil's hair growth effects are androgen-independent, making it effective regardless of DHT levels and complementary to 5-alpha reductase inhibitors like finasteride.

Join others researching Teriparatide — share findings, ask questions, and learn from real experiences Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis drugs that slow bone loss, teriparatide actively stimulates new bone formation. The key to its mechanism is intermittent exposure: while continuous PTH causes bone resorption, daily injections stimulate osteoblasts more than osteoclasts, resulting in net bone formation. Clinical trials show 8% spine bone density increases and 65% reduction in vertebral fractures. Teriparatide binds to PTH type 1 receptors (G-protein coupled receptors) on osteoblasts, osteocytes, and renal tubular cells. This activates PKA and PKC signaling pathways that promote osteoblast activity. The intermittent daily dosing creates an 'anabolic window' where bone formation exceeds resorption. Teriparatide upregulates IGF-1 and FGF2 expression, stimulates bone formation on trabecular and cortical surfaces, and increases bone mineral density through preferential osteoblast stimulation.